Cargando…
Spinal manifestations of CLN1 disease start during the early postnatal period
AIM: To understand the progression of CLN1 disease and develop effective therapies we need to characterize early sites of pathology. Therefore, we performed a comprehensive evaluation of the nature and timing of early CLN1 disease pathology in the spinal cord, which appears especially vulnerable, an...
Autores principales: | Nelvagal, H. R., Dearborn, J. T., Ostergaard, J. R., Sands, M. S., Cooper, J. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867600/ https://www.ncbi.nlm.nih.gov/pubmed/32841420 http://dx.doi.org/10.1111/nan.12658 |
Ejemplares similares
-
Comparative proteomic profiling reveals mechanisms for early spinal cord vulnerability in CLN1 disease
por: Nelvagal, Hemanth R., et al.
Publicado: (2020) -
Gene therapy ameliorates spontaneous seizures associated with cortical neuron loss in a Cln2(R207X) mouse model
por: Takahashi, Keigo, et al.
Publicado: (2023) -
Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease
por: Johnson, Tyler B., et al.
Publicado: (2023) -
Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep
por: Nelvagal, Hemanth R., et al.
Publicado: (2022) -
Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease)
por: Ostergaard, John R.
Publicado: (2023)